CVS Makes Plans To Ration Customers’ Health Care
A health rationing organization’s opinion about so-called quality of life value will soon determine whether CVS customers can receive new prescription drugs and treatments.

CVS Caremark customers throughout America recently received bad news as the retail pharmaceutical chain officially closed on its $69 billion acquisition of Aetna. This is bad news because CVS is now working with a nonprofit “health” advisor that may ration customers’ health care choices.

In August, CVS announced a partnership with the Institute for Clinical and Economic Review (ICER), a nonprofit group that bills itself as a medical review board. But its leadership team and the far-left billionaires footing its bill paint a troubling picture.

ICER was founded by Dr. Steven Pearson. Pearson previously worked with the United Kingdom’s National Institute for Health and Care Excellence (NICE). A pleasant-sounding moniker, NICE is anything but.

Thanks to NICE guidelines, millions of British citizens are on waiting lists at any given time for procedures, hundreds of thousands are waiting for basic diagnostic tests, and thousands of operations are regularly cancelled. During the first quarter of 2018, “the number of British patients waiting 18 weeks or more for treatment increased by 35 percent, which was an increase of 128,575 patients from about 362,000 patients in 2017, to over 490,000 patients in 2018. Additionally, by March 2018, 2,755 patients had waited over a year to be treated, compared to 1,528 patients in 2017,” according to The Heritage Foundation.

NICE is even worse about drug approvals. NICE “has declined to fund [drugs] such as Benlysta, Novartis, Sorafenib and Avastin. The first is a treatment for lupus while the last three can extend the life of cancer patients. The Rare Cancers Forum notes that 16,000 patients annually could benefit from cancer drugs rejected by NICE,” notes the National Center for Public Policy Research’s David Hogberg.

Under ICER’s direction, CVS has set a “threshold of $100,000 per QALY, or quality-of-life years, a benchmark that measures both the quantity and quality of life generated by providing a treatment or some other health care intervention.” In practice, that means ICER’s opinion about the so-called quality of life value will determine whether CVS customers can receive new prescription drugs and treatments.

This means that even if a doctor prescribes a drug for a patient, that individual may find that CVS doesn’t carry that medication if it doesn’t fit ICER’s parameters. Think of it as socialized health care without the socialistic government regime.